A carregar...
Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
OBJECTIVES: Bedaquiline is the first drug of a new class approved for the treatment of TB in decades. Bedaquiline is metabolized by cytochrome P450 (CYP) 3A4 to a less-active M2 metabolite. Its terminal half-life is extremely long (5–6 months), complicating evaluations of drug–drug interactions. Rif...
Na minha lista:
| Publicado no: | J Antimicrob Chemother |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4356204/ https://ncbi.nlm.nih.gov/pubmed/25535219 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dku504 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|